Sudoscan to Exhibit at EASD 2025
in Vienna
Sudoscan is thrilled to announce its participation in the 61st annual meeting of the European Association for the Study of Diabetes (EASD), taking place 15–19 September 2025 at the Vienna Congress & Convention Center in Vienna, Austria.
This premier diabetology meeting attracts 17,000–18,000 international experts yearly, focusing on the latest clinical and biomedical research in diabetes. Sudoscan will present its latest advancements in early detection of diabetic neuropathy, showcasing its non-invasive ESC diagnostic tool at exhibition booth C5.06A.
About the EASD Annual Meeting
EASD, founded in 1965, is a worldwide scientific association with over 3,000 active members dedicated to advancing diabetes research and care. Each year, its annual meeting draws upwards of 17,000 experts to share cutting-edge basic science breakthroughs, clinical trial results, and engage in expert debates.
The 2025 edition will feature a rich and forward‑looking programme:
● Seven halls hosting sessions—Vienna, Paris, London, Mumbai, Sofia, Milan, and Warsaw—along with the Spotlight and Arena stages, covering a wide range of topics from basic science and clinical diabetes to epidemiology, education, and digital health.
● Prestigious award lectures, including the 57th Claude Bernard, 40th Camillo Golgi, 60th Minkowski, and 19th Albert Renold prizes.
● Short Oral Discussions and Lab Talks led by globally renowned researchers such as Dan Drucker, Juleen Zierath, Mikael Rydén, and Roberto Mallone.
● Focused sessions exploring the integration of AI and digital tools in diabetes care.
● A strong emphasis on knowledge sharing and mentorship, with dedicated e‑Learning, expert panels, and tailored content for early-career researchers.
With 1,258 abstracts across 176 sessions, EASD 2025 offers a powerful mix of scientific innovation, clinical insight, and digital health evolution. If you want to learn more about the 2025 EASD’s program, click here.
Sudoscan: A Fast, Scientific Approach to Neuropathy Screening
Sudoscan is a CE‑marked, FDA-cleared Class IIa medical device, widely used across more than 34 countries with over 5,000 units in active clinical use. It uses direct current (≤ 4 V) through stainless steel sensors placed under the hands and feet to calculate Electrochemical Skin Conductance (ESC)—a modern, objective measure of sudomotor function.
● Efficient & Patient-Friendly: The test is completed in under three minutes, requires no special preparation, and is entirely non-invasive.
● Quantitative & Consistent: Outputs numeric ESC values that are reproducible and independent of examiner technique, supporting reliable comparisons across visits and sites.
● Robustly Validated: Findings correlate strongly with established methods such as skin biopsies and QSART.
In diabetology, Sudoscan has proven its worth both for early detection of subclinical neuropathy and for tracking disease progression, including cardiovascular and foot ulcer risk. For more studies on the efficacy of Sudoscan’s technology in diabetes management, visit our publications page.
Visit Us at Booth C5.06A
We invite diabetologists, clinicians, podiatrists, endocrinologists, and researchers to stop by booth C5.06A to:
● Discover how Sudoscan’s fast, non-invasive ESC screening aids in early neuropathy detection.
● Experience live demonstrations illustrating the simplicity and speed of the test.
● Speak with our team about integrating Sudoscan into clinical workflows to enhance patient care and research.
Join us in Vienna Congress & Convention Center to see how Sudoscan is transforming diabetic neuropathy management through accessible, evidence-based diagnostics.
For full program details, registration, and more information, please visit the official EASD 2025 website.
